SOMAÍ Pharmaceuticals

10/04/2026

SOMAÍ will be attending LogiPharma | 14–16 April in Vienna, joining global pharmaceutical leaders to discuss supply chain excellence and operational strategy.

🔷 On Day 3 | 16 April at 13:50, George Bellow, Co-Founder of SOMAÍ, will present a case study:
“Rapidly Scaling Cannabis Operations Worldwide: How to apply pharmaceutical discipline and regulatory agility without losing control – lessons learned for every supply chain.”

🔷 The session will explore how cannabis operations can scale globally while maintaining EU-GMP standards, regulatory compliance, and supply chain integrity.

We look forward to engaging with industry peers and sharing insights on building resilient, compliant global supply chains.

10/04/2026

Portugal has long been the pioneer and undisputed leader in the EU cannabis markets. We are home to the biggest names in the game — Curaleaf, Tilray, SOMAÍ — plus 65 other groups, with more on the way. The reason for this dominance is clear: excellence in pharmaceutical regulations. Portuguese regulators have been the gold standard, understanding cannabis exports and pharmaceutical distribution better than almost anyone globally.

Explore Michael Sassano's article in CannaReporter: https://cannareporter.eu/en/2026/03/13/Portugal-is-the-leader-in-the-European-Union-in-the-cannabis-market--but-this-leadership-is-threatened./

09/04/2026

George Bellow, CO-Founder of SOMAI, will be speaking at Talman House Berlin on 13 April 2026 as part of the panel:

Buyer Beware: Navigating Pitfalls in Global Cannabis Investments

As the global cannabis industry continues to evolve, so do the risks and realities facing investors, operators, and stakeholders. This panel will explore the challenges shaping international cannabis investing — from regulatory volatility and price compression to compliance costs, export limitations, and shifting political sentiment.

It will be a timely conversation on how to assess opportunities more carefully, mitigate risk, and build resilient strategies in an increasingly complex global market.

If you’re attending Talman House Berlin, don’t miss the discussion.

07/04/2026

SOMAÍ at ICBC 2026 🌐

SOMAÍ will be attending ICBC | 13–15 April, joining industry leaders to discuss the continued evolution of the global medical cannabis sector.

🔷 On 14 April, George Bellow, Co-Founder of SOMAÍ, will participate in the panel:
“International Cannabis Investment Opportunities”

🔷 We welcome partners and stakeholders to connect with our team and learn more about:
• SOMAÍ’s EU-GMP cannabinoid-based medicines portfolio
• The Airo medical inhalation system — SOMAÍ’s latest launch in inhalation-based therapies
• Cookies genetics available in regulated medical markets

- Registration: https://internationalcbc.com/register/
- Discount Code: ICBC25S
- Ticket price increase on 9 April

Contact us to schedule a meeting at hello@somaipharma.eu.

02/04/2026

01/04/2026

This April, Michael Sassano, SOMAÍ’s Founder, continues his global tour to strengthen partnerships, support ongoing activities, and help expand patient access to regulated cannabinoid-based medicines.

At SOMAÍ, we’re focused on:
🔹 Growing our global footprint in established and emerging medical markets
🔹 Delivering the most advanced EU-GMP-certified cannabinoid-based extract portfolio
🔹 Driving innovation with new formulations designed for real patient needs

In one of these markets and want to connect with Michael and the team? Reach out: hello@somaipharma.eu

26/03/2026

Australia’s medical cannabis market is not in a race to the bottom — it’s in a race for operational efficiency.

In his latest article, SOMAÍ Founder and Interim CEO Michael Sassano shares his view on why Australia remains one of the most exciting global cannabis markets: rapid product evolution, strong patient demand, a maturing regulatory environment, and growing pressure for sustainable, efficient business models.

As the market moves into what Michael calls “Australia 3.0,” the focus is shifting from short-term disruption to long-term success.

Read the full article published in Cannabiz for Michael’s perspective on where the market is heading next: https://somaipharma.eu/news/its-time-for-australia-to-enter-thenext-phase-of-adolescence-and-startbuilding-for-the-long-term/

24/03/2026

airobrands official, together with SOMAÍ today announced the launch of the Airo Medical Inhalation Device — one of the first CE-certified cannabis medical inhalation devices available in Europe — across pharmacy channels in the German-regulated medical cannabis market.

The system combines the CE-certified Airo Medical Inhalation Device, developed in collaboration with Jupiter Research, with SOMAÍ Pharmaceutical’s EU-GMP-purified inhalation extracts, creating standardized medical options for prescription-based cannabinoid therapies.

“Cannabis extracted products are now entering the medical device phase, allowing popular delivery methods like vaporizers to reach more demographics,” said .sassano.37, Founder and Interim CEO of SOMAÍ. “European and global medical patients are becoming increasingly aware of the benefits of cannabis extracts, and they are now being offered a wider range of dosing options to address their needs and medical indications. We don’t just sell devices to pharmacies; we have created an end-to-end educational and training loop to make the right products and are bringing patient choice to a new age of medical-grade selection for extracts.”

“We are proud to enter Germany as our first European medical market and to support patients with high-quality medical products,” said Richard Yost, CEO of Airo Brands. “By working closely with physicians and pharmacies, our goal is to deliver precise, dependable formulations through a technology-forward inhalation platform. Together with our partners, we are helping advance the standard for pharmaceutical-grade quality in regulated medical markets.

Read the full news here: https://www.einpresswire.com/article/901272299/airo-medical-inhalation-device-launches-in-germany-with-soma-eu-gmp-inhalation-extracts

20/03/2026

Every batch starts here. 🌱
In our mother room, healthy plants are the foundation of consistent medical cannabis production.

Dr. Nigel Gale, Director of Grow & Production, explains why quality starts at the source.

08/03/2026

🔹 International Women’s Day | 8 March

In the medical cannabis and pharma space, progress doesn’t happen by accident — it happens because talented women push science forward, raise the bar for quality, and keep patient needs at the center of every decision.

At SOMAÍ, we’re proud to work alongside women across QA, QC, R&D, cultivation, manufacturing, regulatory, supply chain, commercial teams, and leadership — shaping how cannabinoid-based medicines are developed, produced, and delivered with consistency and care.

🔹 What this day means in our industry

- Better representation in leadership and decision-making
- More diverse perspectives in clinical and product development
- Stronger standards across quality, compliance, and patient communication
- A healthier, more inclusive workplace — and a better patient journey

Today we celebrate the women of SOMAÍ and the wider community — and we stay committed to building an industry where opportunities are real, voices are heard, and innovation benefits everyone.

💙 Happy International Women’s Day.

03/03/2026

This March, Michael Sassano, SOMAÍ’s Founder, will be traveling across key markets to strengthen partnerships, support current activities, and keep expanding patient access to regulated cannabinoid-based medicines:

•⁠ ⁠⁠Bangkok 1-7 March
•⁠ ⁠⁠Melbourne 7-14 March
•⁠ ⁠⁠Brisbane 14-21 March
•⁠ ⁠⁠Portugal 21-26 March
•⁠ ⁠⁠Italy 26 March - 1 April

As SOMAÍ, our focus remains clear:

🔹 Expanding our global distribution footprint across established and emerging medical markets
🔹 Delivering the largest and most advanced EU-GMP-certified cannabinoid-containing pharmaceutical extract portfolio
🔹 Advancing innovation and consistency through new formulations built for real-world patient needs

If you’re in any of these markets and would like to connect with Michael and the team, reach out: hello@somaipharma.eu

19/02/2026

🔵 Celebrating 7 Years of SOMAÍ 🎉

Seven years ago, Michael Sassano and George Bellow founded SOMAÍ with a vision: to build a globally leading pharmaceutical company that would shape the future of EU-GMP cannabinoid-based medicine.

Since then, SOMAÍ has:

🔷 Built a state-of-the-art EU-GMP manufacturing facility
🔷 Achieved EU-GMP licensing within just one year
🔷 Grown into a vertically integrated Multi-Country Operator (MCO) with a presence across Europe, the UK, APAC, and beyond
🔷 Established NovaSoma, our advanced indoor cultivation facility in Lisbon, operating under strict pharmaceutical and environmental controls
🔷 Developed one of the most comprehensive EU-GMP-certified extract portfolios
🔷 Launched multiple product lines, including Essentials, Origins, Senses, and Inhalation Oils
🔷 Advanced scientific research and strategic global partnerships

From a bold idea to a global pharmaceutical platform, SOMAÍ continues to raise the standard for cannabinoid-based medicines — combining cultivation excellence, EU-GMP precision, and international distribution expertise.

Thank you to our team, partners, and patients for being part of this journey.

Here’s to the next chapter. 🌐